Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,469.30 +21.43 (+0.39%) Dow
39,112.16 -299.05 (-0.76%) Nasdaq
17,717.65 +220.84 (+1.26%) Bitcoin USD
61,442.79 +256.26 (+0.42%) CMC Crypto 200
1,273.98 -9.80 (-0.76%)
CHRS Jan 2026 7.000 call
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.1000 |
| Ask | 1.1500 |
| Strike | 7.00 |
| Expiry date | 2026-01-16 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
GlobeNewswireCoherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise Rita Karachun Rita Karachun - Coherus Director REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Kar
GlobeNewswireCoherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained over the dosing interval, establishing proof of mechanism Preclinical data and preliminary clinical results support further evaluation of CHS-114 in combination with the anti-programmed cell death protein 1 (PD-1) antibody, toripalimab-tpzi, and other
Simply Wall St.We Think Some Shareholders May Hesitate To Increase Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation
Key Insights Coherus BioSciences to hold its Annual General Meeting on 29th of May Salary of US$982.9k is part of CEO...
